Regeneron executives sold more than 1 million shares of stock after the share price rose, while Trump bragged about the antibody cocktail, saying “it feels good right away.”
- Over the weekend, both the White House and Trump praised Regernan’s experimental antibody cocktail, REGN-COV2.
- After the video was posted, Regeneron stock surged three percent
- Opening markets on Monday, Regeneron shares rose from 56 4,564 to શેર 600 a share.
- Jogef Goldstein, who sits on the board of directors for Rageron, and head of the SVP and commercial Marion McCourt, sells a total of 10,200 shares.
- Using their stock options allowed the pair to earn more than 1 million in net profit of માટે 740,000 for Goldstein and $ 260,000 for McCourt.
According to recent filings from the Securities and Exchange Commission (SEC), President Donald Trump announced that he was taking his drug to recover from COVID-1, after two Regeneron executives sold two 1 million shares.
Over the weekend, both the White House and Trump praised Regernan’s experimental antibody cocktail that has not been approved by the Food and Drug Administration or has not passed trial.
“They gave me regeneration,” Trump said in a video posted. Twitter About his treatment at Walter Reed National Military Medical Center on October 3rd. ‘It was incredible. I felt better immediately. I felt as good as I did three days ago. ‘
October On October 3, President Trump took to Twitter to share a video where he slammed the Regenson about the antibody cocktail.
After the video was posted, Regeneron stock surged three percent
Trump failed to name the treatment, REGN-COV2.
Regeneron stock surged three percent after the video was posted, NBC News reports.
Opening markets on Monday, Regeneron shares rose from 56 4,564 to એક 600 a share.
Jogan Goldstein, who sits on the board of directors for Regeneron, and head of the SVP and commercial Marion McCourt, sells a total of 10,200 shares.
Using their stock options allowed the pair to make a net profit of over 1 1 million, ગો 740,000 for Goldstein and $ 260,000 for McCourt.
Shares of the company have been sold to B Regiron executives on a regular basis, but coronavirus growth in the U.S. has led to an increase in internal sales activity.
Jogef Goldstein, who sits on the board of directors for Rageron, and head of the SVP and commercial Marion McCourt, sells a total of 10,200 shares.
More than 100 million more stocks have been sold so far than in 2019 and 2018, for a total of $ 248 million so far. That’s an increase of more than 70 percent.
The New York Times reported that Trump’s three family trusts had investments in the company’s main shareholder Regenron and pharmaceutical giant Sanofi.
The President’s 2017 U.S. The filing in Office Fiscal Government Ethics revealed that he has shares in the company but did not appear in his 2020 filing.
A company spokesman said the sale of shares by officials was carried out by a predefined mechanism designed to avoid internal trade allegations.
A company spokesman said the sale of shares by officials was carried out by a pre-determined mechanism, designed to avoid allegations of internal trading.
‘That [Oct. 5] The transactions were carried out as per the 10B5-1 plan, ‘said Alexandra Bowie, a spokeswoman for Regeneron. ‘This is pre-established at a time when the executive / director is not aware of any material, Republican information about Regeronon and is automatically triggered when the stock floats to a certain price.’
The sale raises potential ethical concerns for the Trump administration and drug company executives, according to a group of accountable pharma companies. The group called for an “investigation” into the sale.
The spokesman said “there is a recent case of a clear pattern of President Trump raising shares with his ‘miracle remedy’ hype and promises of taxpayer dollars while drug company officials dump their shares and guarantee whether their treatment will continue.” Said Eli Zupnik.
“There should be a thorough investigation to determine whether there are any irregularities related to the sale of this stock, including any possible government action taken to enrich President Trump or his political advisers.”
.
